But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection.

If you own or are considering buying pharma laggards Pfizer (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), and Merck (NYSE: ...

Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Merck reported second-quarter revenue and adjusted earnings that topped estimates as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and ...

(Reuters) - Pfizer Inc and Merck & Co Inc said they will co-develop Pfizer's experimental type 2 diabetes drug ertugliflozin, both as a standalone product and in combination with other drugs, ...

WASHINGTON (AP) -- The Food and Drug Administration said Thursday it is investigating a possible link between Merck's best-selling Singulair and suicide. FDA said it is reviewing a handful of reports ...

Merck's MK-2214 drug received fast-track designation from the Food and Drug Administration for treatment of Alzheimer's disease. The Rahway, N.J., company said Monday that it would present data this ...